Animal testing rates in medicine have dropped due to a new testing method, as published in a study by Elsevier and Bayer. The study was published in the Journal of Regulatory Toxicology and Pharmacology and it assessed over 1.6 million adverse effects that had been reported to the EU and US regulatory bodies.
Researchers reported that tests on animals do not effectively foresee a positive human response, with different affects happening in humans and animals. These results are encouraging alternative method to be sought and cut out unnecessary animal testing. Despite this evidence having been recognised previously by campaigning groups such as Cruelty Free International, animal testing for a range of products continues.
Dr Matthew Clark, Director of Scientific Services at Elsevier spoke to Pharmatimes, and said: All life companies have a desire to decrease animal testing, and with continued pressure from governments, societies, and animal welfare groups, pharmaceutical organisations are exploring ways to do that.”
The Physicians Committee of Responsible Medicine (PCRM) is encouraging the National Institute of Health to follow a new route, steering it away from animal testing methods and to using computational models, tissue chips and high-throughput screening.
Vice president of PCRM’s research policy, Kristie Sullivan, said: “The National Institutes of Health’s new Roadmap provides a direct route to better protect millions of human and animal lives. It will help replace animal tests, which can fail to predict if a drug or chemical is harmful, with organs-on-chips and other human-relevant methods.”